The Dow Jones Industrial Average (Dow Jones Indices:.DJI) flashed a 60-point gain yesterday driven higher by the tech sector and its old dynamic duo, Microsoft Corporation (NASDAQ...
Keep Reading →
April 10 - News
Is AstraZeneca plc (ADR) (NYSE:AZN) worth your attention right now? The smart money is becoming less confident. The number of long hedge fund bets fell by 2 lately.
Keep Reading →
April 8 - News
Warren Buffett knows what he likes -- and he gets what he likes.
Keep Reading →
April 7 - News
April showers might bring May flowers, but the first week of the new month has already seen several health-care stocks hit full bloom.
Keep Reading →
April 7 - News
Before there was even a fancy term like "nicotine replacement therapy," the Swedish were using nicotine gum in the 1960s to help royal navy submariners manage their nicotine cravings...
Keep Reading →
April 7 - News
Abbott Laboratories (NYSE:ABT) has begun its new future swimmingly.
Keep Reading →
April 5 - News
There are many promising biotech companies out there to choose from. One such company, named Vical Incorporated (NASDAQ:VICL), is targeting a cancer known as Melanoma.
Keep Reading →
April 4 - News
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 2 - News
AbbVie Inc (NYSE:ABBV) investors should be aware of an increase in hedge fund sentiment of late, and we'll compare the company to peers like GlaxoSmithKline plc (ADR) (NYSE:GSK...
Keep Reading →
April 2 - News
I haven't ever heard him say it directly, but it's pretty clear that Warren Buffett has no interest in buying biotech companies.
Keep Reading →
March 31 - Hedge Funds
LONDON -- Two scientists in white lab coats stare into a microscope.
Keep Reading →
March 26 - News
Every year, it appears that flu season starts earlier and earlier, and somehow, every year, the virus mutates into its "most virulent form ever." Sometimes it's a wonder we even...
Keep Reading →
March 25 - News
In this series, we'll highlight four companies in an industry, and compare their "cash king margins" over time, trying to determine which has the greatest likelihood of putting...
Keep Reading →
March 22 - News
It's not uncommon for me to applaud the pharmaceutical industry as a solid long-term investment.
Keep Reading →
March 19 - News
Bacteria have been Public Enemy No. 1 for most of our species' time on Earth.
Keep Reading →
March 18 - News
New issues in U.S. corporate bond markets topped $43 billion last week, with foreign-based borrowers taking down more than half the total.
Keep Reading →
March 18 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 18 - News
LONDON -- You have only a few weeks to use your ISA allowance before the April 5 deadline, so don't fluff this great tax-saving opportunity.
Keep Reading →
March 15 - News
Last year, a number of drugs received FDA approval.
Keep Reading →
March 14 - News
LONDON -- ISA season is upon us again! If you haven't yet used this year's 11,280 pound allowance for a stocks and stocks ISA, you only have a short time left before the April...
Keep Reading →
March 13 - News
As I noted two weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
March 12 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 11 - News
With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
Keep Reading →
March 10 - News
Sarepta Therapeutics Inc (NASDAQ:SRPT) was on fire in 2012, landing at the top of the list of The Motley Fool's best health-care stocks of the year.
Keep Reading →
March 7 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market-leading therapeutic...
Keep Reading →
March 7 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
March 7 - News
Motley Fool health care analyst Max Macaluso and Fool contributor Brian Orelli sat down to discuss Amarin Corporation plc (ADR) (NASDAQ:AMRN) , a biotech that recently launched...
Keep Reading →
March 6 - News
Last year will long be remembered for its remarkable advances in the diagnosis and prevention of HIV; OraSure Technologies gained FDA approval for the first-ever at-home, over...
Keep Reading →
March 6 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
March 5 - News
On Monday, Depomed Inc (NASDAQ:DEPO) is expected to go before the FDA panel with its menopausal hot-flash drug, Serada.
Keep Reading →
March 4 - News
As we've learned in recent years, getting an approval from the Food and Drug Administration is only half the battle.
Keep Reading →
February 25 - News
I think I have uncovered the real reason why Abbott Laboratories (NYSE:ABT) decided to spin off its pharmaceutical division into AbbVie Inc (NYSE:ABBV).
Keep Reading →
February 25 - News
Dynavax Technologies Corporation (NASDAQ:DVAX) is down more than 30% in early trading today following a Food and Drug Administration rejection for its hepatitis B vaccine Heplisav...
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a great way to gain a detailed and thorough perspective on a company and its...
Keep Reading →
February 23 - News
All throughout Wall Street we keep hearing about Amarin Corporation plc (ADR) (NASDAQ:AMRN) being bought out by some type of Big Pharma company in the future. It's all rumors...
Keep Reading →
February 22 - News
Investors who love to receive income from their investments may be understandably frustrated by the current market environment. The Federal Reserve’s monetary policy has short...
Keep Reading →
February 21 - News
I've been examining dividend stocks for nearly a year now, selecting what I feel are the absolute best for my own dividend portfolio.
Keep Reading →
February 21 - News
Microsoft Corporation (NASDAQ:MSFT) actively pursued getting into the social media space, and last summer consummated a courtship with a $1.2 billion acquisition of Yammer.
Keep Reading →
February 20 - News
Horse meat and Wal-Mart Stores, Inc.
Keep Reading →
February 20 - News
Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s largest maker of HIV drugs, but has taken on a number of new initiatives to enter other areas of treatment.
Keep Reading →
February 19 - News
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) started the year strong with a Food and Drug Administration approval for genetic high cholesterol drug Kynamro.
Keep Reading →
February 19 - News
Investors are anxiously waiting for the launch of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai's obesity drug Belviq, which will match up with VIVUS, Inc.
Keep Reading →
February 19 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 18 - News
Some of the best-performing stocks over the past several decades boast long histories of paying dividends to shareholders. Moreover, if these stocks sell for an apparent discount...
Keep Reading →
February 14 - News
Johnson & Johnson (NYSE:JNJ) may offer well-known personal care products such as Listerine and Neutrogena, but it also boasts an impressive portfolio of market leading therapeutic...
Keep Reading →
February 14 - News
How much is trustworthiness actually worth? That somewhat strange thought entered my brain recently after reviewing the latest Harris Physician Pulse Survey.
Keep Reading →
February 13 - News
Warren Buffett has made a name for himself by snatching up companies at deep discounts and holding until he’s captured as much value as possible.
Keep Reading →
February 13 - News
So right now I am trawling through the FTSE 100 and giving my verdict on every member of the blue-chip index.
Keep Reading →
February 13 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said Monday that it got a notice from its partner Sanofi SA (NYSE:SNY) saying that the pharma intends to buy additional shares of the...
Keep Reading →
February 12 - News
